AML patients receive cancer drug DCP-001
December 3, 2018DCprime (spin-off VUmc) announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia. This administration marks the official start of the phase 2 study in the ADVANCE-II study. A total of 20 patients with acute myeloid leukemia (AML), a rare form of leukemia, participate in this study. A recently completed phase I study showed that the cancer drug DCP-001, a vaccine based on dendritic cells, is generally safe and capable of triggering an anti-cancer immune response in patients with AML.
Read here the full press release.
More news
Demonstrator Lab project GlucoEasy wins NWO Open Mind funding of € 50,000
GlucoEasy has won the NWO Open Mind funding of € 50,000. The Open Mind grants are awarded by NWO to technologies with a surprisingly societal application. Measure glucose, but comfortably Diabetics should no longer have to measure their glucose levels by pricking blood. It can perhaps be a lot more comfortable, for example by measuring […]
News
Art meets science at VU based Hybrid Forms Lab
Artistic and scientific research combined into an exciting artwork at new VU-based ArtScience labora-tory Hybrid Forms Lab. GAMeC, the prestigious Italian art museum, acquires artwork from artists Evelina Domnitch and Dmitry Gelfand; artists are based at the VU physics & astronomy department Hybrid Forms laboratory, part of the Demonstrator Lab. The ArtScience Laboratory of the […]
News
SAM Application fights loneliness, selected for the Startup in Residence Programme Amsterdam
Meaningful social contact is the slogan of SAM Application. Elena Köstler and her team are developing a mobile app to combat loneliness among young adults (18-35). They want to bring people together offline via an online platform. “34 million people are socially isolated in the EU. Today, it is more likely to become lonely between […]
News